Abstract
The Ehlers Danlos Syndromes encompass a group of heritable connective tissue disorders with a complex
phenotype affecting multiple body systems. Among these, the hypermobile subtype of EDS (hEDS), is the most
common type of EDS affecting 1 in 500 individuals. The disease phenotype is characterized by hypermobile
joints that lead to musculoskeletal defects, skin manifestations, tissue fragility, and multiple comorbidities. The
healthcare burden associated with hEDS is substantial, with patients often requiring care from a variety of
medical specialists, frequent surgeries and hospitalizations, management of debilitating chronic pain, and
consistent physical and occupational therapy. Despite well-documented inheritance, the genetic causes of hEDS
remain unclear, and diagnosis relies on clinical criteria, resulting in an average 14-year delay in diagnosis. There
are currently no direct treatment options for hEDS other than symptom management. Recent findings from our
group have highlighted the crucial role of a gene family of trypsin-like serine proteases in hEDS. This proposal
will build on these discoveries by exploring the molecular, cellular, and additional genetic mechanisms that
contribute to hEDS pathogenesis and connective tissue homeostasis. We will explore how proteins encoded by
hEDS genes regulate collagen fibrillogenesis (Aim 1), investigate their contribution of mast cells to altered
extracellular matrix (Aim 2), and perform genome wide association studies (GWAS) to reveal common variants
associated with hEDS and connective tissue biology (Aim 3). By employing our unique and novel mouse models
and leveraging our extensive clinical genetic registry, we aim to gain novel insights into the pathogenesis of
hEDS and its related comorbidities. From these discoveries, we aim to accelerate the development of targeted
therapies for hEDS, create more accurate molecular diagnostic tools and ultimately alleviate the burden on
patients and the healthcare system.